Medera

Founded in 2021 and based in Cambridge, Massachusetts, Medera is a private, clinical-stage biotech pioneering next-generation therapies for cardiovascular and related diseases. The company's core differentiation lies in its integrated platform combining a proprietary intracoronary delivery methodology with a sophisticated human mini-Heart tissue model for discovery and validation. Led by a team of seasoned experts, Medera is advancing a pipeline that strategically addresses high-burden common diseases and niche rare disorders, aiming to create affordable and deliverable genetic medicines. Its operational address is in Boston, MA.

Integrated platform featuring a proprietary intracoronary delivery methodology for gene/cell therapy and a bioengineered human mini-Heart tissue model with automated screening for preclinical discovery and validation.

Medera competes in the emerging field of cardiac gene therapy against other biotechs and large pharma, such as Tenaya Therapeutics, Rocket Pharmaceuticals, and Bayer. Its differentiation hinges on its proprietary intracoronary delivery system and human-relevant mini-Heart screening platform. In rare diseases like DMD-CM, it faces competition from companies like Sarepta and Pfizer.